High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma

Journal of Contemporary Brachytherapy

Volumn 7, Issue 1, 2015, Pages 35-40

  Damast, Shari ^a   Higgins, Susan A ^a   Ratner, Elena ^a   De Leon, Maria C ^a   Mani, Sheida ^a   Silasi, Dan Arin ^a   Azodi, Masoud ^a   Santin, Alessandro ^a   Rutherford, Thomas ^a   Schwartz, Peter E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Chemotherapy; Endometrial cancer; Papillary serous

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ASCITES FLUID CYTOLOGY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; DISSECTION; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; INTRA VAGINAL BRACHYTHERAPY; LUNG METASTASIS; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OMENTECTOMY; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; RADIATION DOSE; RECURRENCE FREE SURVIVAL; REVIEW; SALPINGOOOPHORECTOMY; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA;

EID: 84924859601     PISSN: 1689832X     EISSN: 20812841     Source Type: Journal    
DOI: 10.5114/jcb.2015.48539     Document Type: Review

References (26)

1. Hendrickson M, Ross J, Eifel P et al. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. The Am J Surg Pathol 1982; 6: 93-108.
2. Boruta DM, 2nd, Gehrig PA, Fader AN et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009; 115: 142-153.
3. Sutton G, Axelrod JH, Bundy BN et al. Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 100: 349-354.
4. Martinez AA, Weiner S, Podratz K et al. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gynecol Oncol 2003; 90: 537-546.
5. Kelly MG, O'Malley DM, Hui P et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005; 98: 353-359.
6. Goldberg H, Miller RC, Abdah-Bortnyak R et al. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol 2008; 108: 298-305.
7. Fader AN, Drake RD, O'Malley DM et al. Platinum/taxane- based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 2009; 115: 2119-2127.
8. Turner BC, Knisely JP, Kacinski BM et al. Effective treatment of stage I uterine papillary serous carcinoma with high doserate vaginal apex radiation (192Ir) and chemotherapy. Int J Rad Oncol Biol Phys 1998; 40: 77-84.
9. Alektiar KM, Makker V, Abu-Rustum NR et al. Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. Gynecol Oncol 2009; 112: 142-145.
10. Kiess AP, Damast S, Makker V et al. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol 2012; 127: 321-325.
11. Barney BM, Petersen IA, Mariani A et al. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer. Int J Rad Oncol Biol Phys 2013; 85: 109-115.
12. Eldredge-Hindy HB, Eastwick G, Anne PR et al. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer. J Contemp Brachytherapy 2014; 6: 262-270.
13. Townamchai K, Berkowitz R, Bhagwat M et al. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. Gynecol Oncol 2013; 129: 18-21.
14. Small W, Jr., Beriwal S, Demanes DJ et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 2012; 11: 58-67.
15. Landrum LM, Nugent EK, Zuna RE et al. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol 2014; 132: 50-54.
16. Nag S, Gupta N. A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Rad Oncol Biol Phys 2000; 46: 507-513.
17. DuBeshter B, Estler K, Altobelli K et al. High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer. Gynecol Oncol 2004; 94: 383-386.
18. Sorbe B, Straumits A, Karlsson L. Intravaginal high-dose-rate brachytherapy for stage I endometrial cancer: a randomized study of two dose-per-fraction levels. Int J Rad Oncol Biol Phys 2005; 62: 1385-1389.
19. https://www.msbi.nl/promise/Projects/PORTEC4.aspx, last accessed 03/02/2014.
20. rd Annual ASTRO Meeting. Abstract 2553. Int J Rad Oncol Biol Phys 2011; 81: S475.
21. th Annual ASTRO Meeting. Abstract 240. Int J Rad Oncol Biol Phys 2014; 90: S111.
22. Ly D, Rowley BD, Dodson MK et al. Adjuvant radiation in early stage, unfavorable histology endometrial carcinoma is associated with improved local control and survival. Gynecol Oncol 2014; 133: 250-255.
23. Mehta N, Yamada SD, Rotmensch J et al. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Rad Oncol Biol Phys 2003; 57: 1004-1009.
24. Slomovitz BM, Burke TW, Eifel PJ et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003; 91: 463-469.
25. Jhingran A, Ramondetta LM, Bodurka DC et al. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol 2013; 129: 304-309.
26. Desai NB, Kiess AP, Kollmeier MA et al. Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy. Gynecol Oncol 2013; 131: 604-608.